Akari Therapeutics (AKTX) Assets (2011 - 2026)

Akari Therapeutics (AKTX) has 16 years of Assets data on file, last reported at $33.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 33.5% year-over-year to $33.9 million; the trailing twelve-month figure through Mar 2026 stood at $33.9 million (down 33.5% YoY), and the FY2025 full-year result was $47.9 million, down 5.28% from the prior year.
• Assets slipped to $33.9 million in Q1 2026, from $47.9 million in the prior quarter.
• In the past five years, Assets ranged from a high of $51.0 million in Q1 2025 to a low of $2.7 million in Q3 2024.
• A 5-year average of $28.0 million and a median of $33.9 million in 2026 frame the typical range for Assets.
• Across the five-year window, Assets slumped 68.52% in 2023 and jumped 1738.35% in 2025, its largest moves.
• Tracing AKTX's Assets over 5 years: stood at $13.8 million in 2022, then tumbled by 68.52% to $4.4 million in 2023, then soared by 1061.01% to $50.6 million in 2024, then dropped by 5.28% to $47.9 million in 2025, then fell by 29.24% to $33.9 million in 2026.
• Business Quant data shows AKTX's Assets at $33.9 million in Q1 2026, $47.9 million in Q4 2025, and $45.4 million in Q3 2025.